Bandello F, Staurenghi G, Ricci F, et al. - Researchers conducted this 12-month, prospective, multicentre, open-label, single arm, pragmatic interventional study to assess the safety and tolerability of ranibizumab 0.5 mg in patients with uni/bilateral neovascular age-related macular degeneration and best-corrected visual acuity (BCVA) < 2/10 and/or second eye affected, irrespective of BCVA. As per the approved label, ranibizumab was administered to 941 patients aged ≥ 50 years monthly until maximum stable visual acuity was achieved (initially, three or more injections may be needed). Data reported that the mean number of ranibizumab injections during the study was 5.4 (2.9)/10.6 (5.0) injections in uni/bilaterally treated individuals. The authors concluded that ranibizumab displayed good safety and tolerability in these patients with a low incidence of adverse events (AEs) and AE of special interest.